Clinical study on treatment of continuous blood purification combined with Ulinastatin for patients with severe sepsis

Objective:To investigate the effect of continuous blood purification combined Ulinastatin on inflammation of patients with severe sepsis,as well as the clinical outcomes.Methods: 70 cases with severe sepsis subsequently divided into control group(n=22),CBP group(n=23) and CBP+ Ulinastatin group(n=25).The control group received classical treatment.the CBP group was added with continuous blood purification,and the CBP+ Ulinastatin group with Ulinastatin.The development of disease was observed,and the blood biochemical parameters,coagulation index and arterial blood gas analyses were evaluated before and after treatment.ELISA was used to quantify the serum concentration of CRP.Results: ①Compared with control and CBP group,the case-fatality rate,length of ICU stay and rate of MODS significantly decreased in CBP+ Ulinastatin group(P0.05).②After treatment,the APACHE II score CBP+Ulinastatin group fell to 15.46±3.96,significantly lower than control group(18.06±4.25) and CBP group(17.14±5.55)(P0.05).③ The levels of BUN and HR was lowest in CBP+ Ulinastatin group,followed successively by CBP and control group.(P0.05) But no difference was found in PH,HCO3-and MAP among groups(P0.05).④ After treatment,the levels of serum CRP and WBC significantly decreased,especially in CBP+Ulinastatin group(P0.05).⑤PT,TT and APTT increased in all patients,and PLT decreased.The PT and APTT was shorter in CBP+Ulinastatin group than control and CBP group(P0.05).Conclusion: Combination of continuous blood purification and Ulinastatin for the treatment of severe sepsis can inhibit inflammatory response,reduce the severity of the sepsis,and improve prognosis.